An Implantable Scaffold Sequentially Releasing STING Agonist and B7‐H3 Antibody for Bone Metastasis Immunotherapy (Adv. Sci. 33/2026)

Scaffold-Mediated Bone Metastasis Immunotherapy In their Research Article (DOI: 10.1002/advs.202520642), Yuhu Dai, Mingqiang Li, Xinsheng Peng, Chuandong Lang, and co-workers developed an implantable scaffold co-loaded with STING agonist MSA-2 and B7-H3 antibody-encapsulated CaCO3 microparticles for bone metastasis immunotherapy. The scaffold sequentially releases MSA-2 first to activate STING signaling and promote effector T cell infiltration, followed by pH-triggered B7-H3 antibody release to block the upregulated B7-H3 checkpoint and prevent T cell exhaustion. This innovative strategy effectively converts the “cold” tumor microenvironment to a “hot” state, generating robust antitumor immunity with minimal systemic toxicity, representing a promising localized immunotherapeutic approach for preventing postoperative tumor recurrence.